Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see if participants with anemia due to their type of MDS or
MDS/MPN will experience a more decreased need for regular blood transfusions if they take
luspatercept plus best supportive care, and what effect, good and/or bad, luspatercept has on
them and their anemia due to MDS or MDS/MPN. The safety and tolerability of luspatercept will
also be evaluated in this study.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute